Bristol-Myers Squibb Registers Securities on NYSE

Ticker: CELG-RI · Form: 8-K · Filed: Jan 8, 2024 · CIK: 14272

Bristol Myers Squibb Co 8-K Filing Summary
FieldDetail
CompanyBristol Myers Squibb Co (CELG-RI)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.10
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, debt, common-stock, nyse

TL;DR

**BMY just confirmed its stock and bonds are properly listed on the NYSE, standard stuff.**

AI Summary

Bristol-Myers Squibb Company filed an 8-K on January 8, 2024, to register its Common Stock ($0.10 Par Value), 1.000% Notes due 2025 (BMY25), and 1.750% Notes due 2035 (BMY35) on the New York Stock Exchange. This filing ensures that these specific securities are properly listed and traded, providing transparency and liquidity for investors. For shareholders, this confirms the continued official trading of their BMY stock and bonds on a major exchange, which is a standard operational update.

Why It Matters

This filing confirms the official listing of Bristol-Myers Squibb's common stock and specific debt notes on the NYSE, which is crucial for market liquidity and investor confidence.

Risk Assessment

Risk Level: low — This 8-K is a routine administrative filing confirming existing security registrations, posing no new financial or operational risks.

Analyst Insight

This is a routine administrative filing. Investors should view this as standard operational transparency and not expect any immediate market-moving impact from this specific 8-K.

Key Numbers

  • $0.10 — Par Value (Par value of Bristol-Myers Squibb's Common Stock)
  • 1.000% — Interest Rate (Interest rate for Notes due 2025)
  • 1.750% — Interest Rate (Interest rate for Notes due 2035)
  • 2025 — Maturity Year (Maturity year for BMY25 Notes)
  • 2035 — Maturity Year (Maturity year for BMY35 Notes)

Key Players & Entities

  • BRISTOL-MYERS SQUIBB COMPANY (company) — the registrant filing the 8-K
  • New York Stock Exchange (company) — the exchange where securities are registered
  • $0.10 (dollar_amount) — par value of Common Stock

FAQ

What is the purpose of Bristol-Myers Squibb's 8-K filing on January 8, 2024?

The purpose of the 8-K filing on January 8, 2024, is to report the registration of certain securities pursuant to Section 12(b) of the Securities Exchange Act of 1934, specifically its Common Stock, 1.000% Notes due 2025, and 1.750% Notes due 2035 on the New York Stock Exchange.

Which specific securities are registered in this 8-K filing?

The specific securities registered are Common Stock, $0.10 Par Value (Trading Symbol: BMY), 1.000% Notes due 2025 (Trading Symbol: BMY25), and 1.750% Notes due 2035 (Trading Symbol: BMY35).

On which exchange are these securities registered?

All the listed securities – Common Stock, 1.000% Notes due 2025, and 1.750% Notes due 2035 – are registered on the New York Stock Exchange.

What is the par value of Bristol-Myers Squibb's Common Stock as stated in the filing?

The par value of Bristol-Myers Squibb's Common Stock is stated as $0.10.

What are the maturity dates and interest rates for the notes mentioned in the filing?

The filing mentions 1.000% Notes due 2025 and 1.750% Notes due 2035, indicating maturity in 2025 with a 1.000% interest rate and maturity in 2035 with a 1.750% interest rate, respectively.

Filing Stats: 620 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-01-08 10:29:24

Key Financial Figures

  • $0.10 — ange on which registered Common Stock, $0.10 Par Value BMY New York Stock Exchan

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On January 8, 2024, Bristol-Myers Squibb Company (the "Company") posted an investor presentation to its website at: www.bms.com/investors/events-and-presentations.html. A copy of the investor presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise be subject to the liabilities thereof, nor shall it be incorporated by reference into any filing by the Company under the Exchange Act or under the Securities Act of 1933, as amended, whether made before or after the date hereof regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits The following exhibit is included as part of this Current Report on Form 8-K: Exhibit No. Description 99.1 Investor presentation of Bristol-Myers Squibb Company dated January 8, 2024. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). EXHIBIT INDEX Exhibit No. Description 99.1 Investor presentation of Bristol-Myers Squibb Company dated January 8, 2024. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRISTOL-MYERS SQUIBB COMPANY Dated: January 8, 2024 By: /s/Kimberly M. Jablonski Name: Kimberly M. Jablonski Title: Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.